Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva pharmaceuticals slovakia s.r.o., slovensko - fulvestrant - 34 - antihormona

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ever valinject gmbh, rakúsko - fulvestrant - 34 - antihormona

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare polska sp. z o.o., poľsko - fulvestrant - 34 - antihormona

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fresenius kabi s.r.o., Česká republika - fulvestrant - 34 - antihormona

Evropská unie - slovenština - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitída, meningokoková - vakcíny - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vipharm s.a., poľsko - fulvestrant - 34 - antihormona

Evropská unie - slovenština - EMA (European Medicines Agency)

accord healthcare s.l.u. - cabazitaxel - prostatic neoplasms, kastrácia-odolný - antineoplastické činidlá - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - fulvestrant - 34 - antihormona

Evropská unie - slovenština - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastické činidlá - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Evropská unie - slovenština - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).